Jurkat ICOS/ICOS-L Agonist Assay - Human ICOS Reporter Jurkat Cells

NFAT-Lucia reporter T lymphocytes

ABOUT

Agonist screening assay for ICOS/ICOS-L axis

InvivoGen offers a cellular assay specifically designed for screening antibody-, Fc-fusion protein-, or small-molecule agonists of the ICOS/ICOS-L immune checkpoint (IC) axis:

  • Jurkat-Lucia™ hICOS: Reporter T cells

 

Inducible Co-stimulator (ICOS, CD278) is an immunostimulatory IC and a member of the CD28 superfamily. Expression of ICOS is rapidly induced in  CD4+ and CD8+ T cells upon their activation, whereas its ligand ICOS-L (also known as CD275), is mostly expressed by antigen-presenting cells [1]. 

More details More details

 

Assay principle:

This assay relies on the monitored activation of Jurkat-Lucia™-ICOS cells which express a hICOS-CD3ζ fusion protein along with the Lucia luciferase reporter gene under the control of an ISG54 minimal promoter fused to six NFAT response elements. CD3ζ is a key component of the T-cell receptor (TCR) and CD3 complex that triggers TCR downstream signaling.
In the presence of a potent ICOS agonist, such as hICOS-L-Fc, hICOS-CD3ζ triggers NFAT activation and Lucia production. Activation of the reporter T cells can be readily measured using QUANTI-Luc™ 4 Lucia/Gaussia detection reagent (see Figures).

T-cell key features:

  • Stable hICOS-CD3ζ expression
  • NFAT-inducible Lucia luciferase reporter activity

 

InvivoGen also offers Jurkat-Raji ICOS/ICOS-L (Bio-IC™), a cellular assay for screening antagonists of the ICOS/ICOS-L axis.

 

Read our review Read our review on Immune Checkpoint Blockade

Learn more about Immune Checkpoint Antibodies Learn more about Immune Checkpoint Antibodies.

 

Reference:

1. Amatore, F. et al. 2020. Role of ICOS in cancer immunotherapy. Expert Opin Biol Ther 20, 141-150.

Disclaimer:  These cells are for internal research use only and are covered by a Limited Use License (See Terms and Conditions). Additional rights may be available.

SPECIFICATIONS

Specifications

Cell type
Lymphoblastic
Growth properties
Suspension
Tissue origin
Human T lymphocytes
Reporter gene
Lucia®
Antibiotic resistance
Blasticidin
Zeocin®
Growth medium

Complete IMDM (see TDS)

Mycoplasma-free

Verified using Plasmotest

Quality control

Each lot is functionally tested and validated.

CONTENTS

Contents

  • Product: 
    Jurkat-Lucia™ hICOS Cells
  • Cat code: 
    jktl-icos
  • Quantity: 
    3-7 x 10^6 cells
Includes:
  • 1 ml of Blasticidin (10 mg/ml)
  • 1 ml of Zeocin® (100 mg/ml)
  • 1 ml of Normocin™ (50 mg/ml). Normocin™ is a formulation of three antibiotics active against mycoplasmas, bacteria, and fungi.
  • 1 tube of QUANTI-Luc™ 4 Reagent, a Lucia luciferase detection reagent (sufficient to prepare 25 ml)

Shipping & Storage

  • Shipping method:  Dry ice
  • Storage:

    • Liquid nitrogen vapor
    Stability: 20 passages

Details

Inducible Co-stimulator (ICOS, CD278) is an immunostimulatory IC and a member of the CD28 superfamily. Expression of ICOS is rapidly induced in  CD4+ and CD8+ T cells upon their activation, whereas its ligand ICOS-L (also known as CD275), is mostly expressed by antigen-presenting cells [1]. The interaction between ICOS and ICOS-L delivers a secondary co-stimulatory signal through the activation of the transcription factor AKT, which promotes T cell proliferation and differentiation as well as the production of cytokines  [1]. In tumor immunity, ICOS is involved in the amplification of the anti-tumor cytotoxic CD8+ T cell response, as well as the 'pro-tumor' function and maintenance of regulatory T cells (Tregs). Therefore, both agonistic and antagonistic monoclonal antibodies (mAbs) targeting this pathway are being investigated in combinational cancer immunotherapy [2]. Notably, ICOS agonistic mAbs have been shown to potentiate the effects of anti-CTLA-4 mAbs [3]. 

 

References:

1. Amatore, F. et al. 2020. Role of ICOS in cancer immunotherapy. Expert Opin Biol Ther 20, 141-150.
2. Solinas, C. et al. 2020. The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy. ESMO Open 5.
3. Soldevilla, M.M. et al. 2019. ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity. Mol Ther 27, 1878-1891.

DOCUMENTS

Documents

Jurkat-Lucia™ hICOS Cells

Technical Data Sheet

Validation Data Sheet

Safety Data Sheet

Certificate of analysis

Need a CoA ?

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?